The insider selling is immaterial relative to market cap and lacks a bearish catalyst. No cross-filing context (earnings, late filing, or agreement) amplifies the signal. Monitor for any upcoming regulatory or pipeline catalysts, but this cluster alone does not warrant a trading action.
PTCT drugs
PTCT drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 17 $78.59entry
- T+1 · 4mo ago −0.74%α −0.58% · $78.01
- T+5 · 4mo ago −2.25%α −1.67% · $76.82
- T+20 · 3mo ago −8.77%α −13.21% · $71.70
- T+60 · 5w ago −19.94%α −24.62% · $62.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three PTC Therapeutics insiders, including the CFO and Chief Technical Ops Officer, sold a total of $1.40M in stock over a one-week window. The sales are modest relative to the $6.5B market cap (0.02%) and are likely driven by routine portfolio diversification or tax planning, not a bearish signal on fundamentals.
Key Financial Metrics
Key Facts
- Three insiders sold shares totaling $1.40M between July 7-14, 2026.
- CFO Pierre Gravier sold 3,494 shares at $80.35 for $280,743.
- Chief Technical Ops Officer Neil Almstead sold 2,500 shares at $90.25 for $222,000.
- Director Mary L. Smith sold 10,000 shares at $90.00 for $900,000.
- Total sales represent approximately 0.02% of PTCT's $6.5B market cap.
- No open-market purchases were reported in the cluster.
Financial Impact
Total insider sales of $1.40M represent 0.02% of market cap, trivial and routine.
Risk Factors
- Insider sales could accelerate if a negative catalyst emerges (e.g., clinical trial failure, regulatory setback).
- The CFO's sale at a lower price ($80.35) than the other two ($90.00-$90.25) may indicate a staggered exit, but the difference is within normal trading range.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PTCT-1784275361376 |
Track record
29 reports on PTCT
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +19.01% at T+60 after the Apr 28, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $62.09 Now $60.97 −1.80% settles Nov 17
- Nov 16, 2026today 144 Neutral 2/10 Entry $62.10 Now $60.97 −1.82% settles Nov 17
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $63.45 Now $60.97 −3.91% settles Nov 17
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $64.14 to $64.91 Now $60.97 −4.94% ▲ +1.20% −0.12% vs SPY
- Nov 3, 202613d ago 8-K Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 3, 202613d ago Press Release Neutral 3/10 Entry $68.12 to $68.97 Now $60.97 −10.50% ▲ +1.25% −0.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $68.12 to $68.97 Now $60.97 +10.50% ▼ −1.25% +0.40% vs SPY
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $59.97 to $60.88 Now $60.97 +1.67% ▲ +1.52% +2.00% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $63.02 to $64.46 Now $60.97 −3.25% ▲ +2.29% +2.67% vs SPY
- Oct 16, 20264w ago Insider Cluster Neutral 3/10 Entry $61.53 to $62.92 Now $60.97 −0.91% ▲ +2.26% +1.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers